Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Deposition of Inhaled Amikacin-Loaded Liposomes
NCT05999942Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Jun 2004
- Primary completion
- Jun 2004
- Modality
- Small Molecules, Lipid-based Nanoparticles
01
Overview
Phase 1, open-label, single-arm trial of amikacin liposome inhalation suspension in Mycobacterium avium complex lung disease, sponsored by Insmed Incorporated. Primary endpoint: Pulmonary Deposition of Radiolabelled Amikacin-loaded Liposomes Measured as Percentage Retention of Emitted Dose Deposited in the Lungs. Started Jun 2004; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT05999942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999942.